Consensus Moderna, Inc.

Equities

MRNA

US60770K1079

Market Closed - Nasdaq 16:00:00 2024-05-24 EDT 5-day change 1st Jan Change
166.6 USD +1.59% Intraday chart for Moderna, Inc. +18.15% +67.53%

Evolution of the average Target Price on Moderna, Inc.

Price target over the last 5 years

History of analyst recommendation changes

6db1e41915399dae96bd00c45d2b.-7XFW_QRn2q6ghpyzaAkTFFiwdYacmFPw1yQAutgfW0.s_uiKc1jpiz0xzcjnMt2Ih038LxOPjkm8hbEUaILEwyWgIJvgSXIJ4LneQ~633740effe27d01907b80a7d19088ef4
Moderna Insider Sold Shares Worth $1,909,863, According to a Recent SEC Filing MT
Moderna Insider Sold Shares Worth $1,912,350, According to a Recent SEC Filing MT
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program MT
ANALYST RECOMMENDATIONS : Nike, Roblox, Starbucks, Walmart, Deckers Outdoor... Our Logo
Evercore ISI Initiates Moderna With In Line Rating, $120 Price Target MT
Moderna Insider Sold Shares Worth $1,825,220, According to a Recent SEC Filing MT
Deutsche Bank Raises Moderna's Price Target to $85 From $70 MT
UBS Adjusts Moderna Price Target to $151 From $143, Maintains Buy Rating MT
News Highlights : Top Financial Services News of the Day - Monday at 11 AM ET DJ
Moderna Insider Sold Shares Worth $1,663,855, According to a Recent SEC Filing MT
Jefferies Adjusts Price Target on Moderna to $155 From $125 MT
Oppenheimer Adjusts Price Target on Moderna to $163 From $142 MT
Goldman Sachs Adjusts Price Target on Moderna to $204 From $206 MT
Leerink Adjusts Price Target on Moderna to $60 From $59 MT
Morgan Stanley Adjusts Price Target on Moderna to $95 From $89 MT
Jefferies & Co Adjusts Moderna Price Target to $155 From $125 MT
Goldman Sachs Adjusts Moderna Price Target to $204 From $206 MT
Morgan Stanley Raises Price Target on Moderna to $95 From $89, Keeps Equalweight Rating MT
RBC Raises Price Target on Moderna to $135 From $125 on 'More Prudent Financial Outlook,' Keeps Outperform Rating MT
ANALYST RECOMMENDATIONS : Alphabet, Amgen, Starbucks, PayPal, Moderna... Our Logo
MODERNA : price target raised by Oddo BHF CF
RBC Raises Price Target on Moderna to $135 From $125 MT
Chardan Research Lowers Metagenomi's PT to $17 From $21 on Heels of Announced Termination of Collaboration With Moderna, Keeps Buy Rating MT
Moderna Secures Contract to Supply 12.5 Million COVID-19 Vaccine Doses to Brazil MT
Moderna Insider Sold Shares Worth $1,575,300, According to a Recent SEC Filing MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
166.6 USD
Average target price
138.5 USD
Spread / Average Target
-16.86%
High Price Target
310 USD
Spread / Highest target
+86.06%
Low Price Target
60 USD
Spread / Lowest Target
-63.99%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Moderna, Inc.

Evercore ISI
Deutsche Bank Securities
UBS
Jefferies & Co.
Oppenheimer
Goldman Sachs
Leerink Partners
Morgan Stanley
RBC Capital Markets
Redburn
HSBC
Canaccord Genuity
RBC Luca Issi
JPMorgan Chase
Argus
TD Cowen
William Blair & Co.
Guggenheim
SVB Securities LLC
Cowen
Chardan Research
Piper Sandler
SVB Leerink
BofA Securities
Wolfe Research
Barclays
Chardan
J.P. Morgan Chase
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. Consensus Moderna, Inc.